CIMVA Clinical Decision Support Software

Therapeutic Monitoring Systems is developing CIMVA - innovative clinical decision support software for use in the ICU. CIMVA software (continuous individualized multiorgan variability analysis) integrates with patient vital sign monitoring systems and provides health professionals with objective insights into subtle but clinically relevant changes in patient health status.

CIMVA represents a groundbreaking advance to continuous ICU monitoring, providing a novel, software-based, comprehensive integration of patterns of variation over time. CIMVA uses sophisticated waveform analysis and variability analytics to continually monitor changes in patient vital sign variability. CIMVA characterizes variability measured over intervals-in-time (as opposed to traditional point-in-time analysis), and then simultaneously tracks changes in variability over time for multiple organ systems.

Critically ill patients have vital signs that are less complex and more regular than healthy patients, and the degree of reduction in complex variability correlates with severity of illness. Numerous peer-reviewed clinical studies have demonstrated the strong correlation between changes in physiological variability and underlying patient health. Recent clinical evidence is demonstrating that continuous monitoring of multiorgan variability can detect clinical deterioration as well as evaluate response to intervention.

Conceived, researched and developed by an ICU intensivist, CIMVA software is designed to provide medical professionals with critical care diagnostic and predictive decision support based on objective measurement and understanding of changes of the patient’s physiology. CIMVA complements the existing standard of care in the ICU and leverages clinical experience and intuition, assisting physicians to make earlier and more accurate evidence-based clinical decisions, thereby improving patient outcomes and the efficiency of care.

The subject of issued and pending patents, CIMVA is now undergoing final development in preparation for regulatory approval for clinical use.